ondansetron adding in PCA

PreclinicalSmall molecule

ondansetron adding in PCA is one of 7 small molecule programs targeting Patient-Controlled Analgesia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patient-Controlled AnalgesiaCompleted

Patient-Controlled AnalgesiaPreclinical

Completed

Competition

Competitive Landscape

6 competitors in Patient-Controlled Analgesia

#DrugCompanyPhaseTrials

MS Contin

HHikma Pharmaceuticals LLC

Approved

2 2

Oxycontin

PProtega

Approved

1 3

Dynastat

Pfizer

Preclinical

1 4

Acupan

YYonsei University

Preclinical

1 5

Ansaid

PPharmacia and Upjohn

Preclinical

1 6

Ramosetron

Astellas

Preclinical

1 7

ondansetron adding in PCA

KKhon Kaen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Patient-Controlled Analgesia1 trial

Antiemetic Effect of the Addition of Ondansetron to the Morphine Solution in Patient-Controlled Analgesia (PCA)

Completed·KKhon Kaen University·N/A·NCT00199329·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ondansetron adding in PCA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ondansetron adding in PCA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ondansetron adding in PCA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Khon Kaen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKhon Kaen University

ondansetron adding in PCA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Patient-Controlled Analgesia1 trial

References

Drug Info

Quick Facts

Related News